Novogen Ltd (NVGN)

1.69
0.07 3.90
NASDAQ : Health Care
Prev Close 1.76
Open 1.70
Day Low/High 1.69 / 1.70
52 Wk Low/High 1.79 / 3.98
Volume 2.96K
Avg Volume 44.50K
Exchange NASDAQ
Shares Outstanding 19.32M
Market Cap 32.65M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Novogen Submits Investigational New Drug (IND) Application To The US FDA For Cantrixil(TM) In Ovarian Cancer

Novogen Submits Investigational New Drug (IND) Application To The US FDA For Cantrixil(TM) In Ovarian Cancer

- Cantrixil (TRX-E-002-1) is Novogen's lead development candidate, and is being developed as a therapy for patients with ovarian cancer

Novogen Patent Covering Anisina(TM) Has Proceeded To Grant

Novogen Patent Covering Anisina(TM) Has Proceeded To Grant

- Cornerstone patent covering Anisina (ATM-3507) granted in Australia

Novogen Patent Covering Cantrixil And Trilexium Has Proceeded To Grant

Novogen Patent Covering Cantrixil And Trilexium Has Proceeded To Grant

- Cornerstone patent covering Cantrixil and Trilexium granted in Australia

Novogen Announces Changes To The Board With New Chairman And Deputy Chairman Appointed

Novogen Announces Changes To The Board With New Chairman And Deputy Chairman Appointed

- Incoming CEO James Garner appointed to the Board of Novogen

Novogen Patent Covering Cantrixil And Trilexium Accepted In Australia

Novogen Patent Covering Cantrixil And Trilexium Accepted In Australia

- Cornerstone patent covering Cantrixil and Trilexium accepted in Australia

Preclinical Studies Justify Mode Of Delivery And Dosing Regimen For Anisina

Preclinical Studies Justify Mode Of Delivery And Dosing Regimen For Anisina

Intravenous Anisina drug product identified

Novogen Announces The Outcome Of A Comprehensive Science Review

Novogen Announces The Outcome Of A Comprehensive Science Review

- Novogen will focus the development programs for each of our three lead candidates to achieve the earliest possible initiation of clinical studies. We affirm our goal to have two products enter clinical development in 2016

Newly Appointed Acting CEO Outlines Immediate Plans For Novogen

Newly Appointed Acting CEO Outlines Immediate Plans For Novogen

Company Confirms Its Commitment to Bringing Technology Platforms to the Clinic

Pre-clinical Studies Suggest Anisina May Improve Chemotherapy Effectiveness In Childhood Cancer

Pre-clinical Studies Suggest Anisina May Improve Chemotherapy Effectiveness In Childhood Cancer

- Potential to improve effectiveness of chemotherapy

Novogen (NVGN) Stock Falls Today on Private Placement

Novogen (NVGN) Stock Falls Today on Private Placement

Shares of Novogen (NVGN) were down in late morning trading Monday after the Australian and U.S. biotechnology company announced it had conducted a private placement and offered rights to shareholders.

Novogen (NVGN) Stock Rises Today After Announcing Brain Cancer Treatment Collaboration

Novogen (NVGN) Stock Rises Today After Announcing Brain Cancer Treatment Collaboration

Shares of Novogen (NVGN) were up Friday after the company announced an MOU with the Feinstein Institute for Medical Research of New York to collaborate on brain cancer treatments.

Novagen (NVGN) Stock Spiked Today on Melanoma Treatment Study Results

Novagen (NVGN) Stock Spiked Today on Melanoma Treatment Study Results

Novagen (NVGN) shares rose double digits today after announcing promising results from its melanoma treatment study.

Novogen And CanTx Announce Potency Of Intra-Peritoneal Trx-1 Confirmed Against Chemo-Resistant Ovarian Cancer Stem Cells

Novogen And CanTx Announce Potency Of Intra-Peritoneal Trx-1 Confirmed Against Chemo-Resistant Ovarian Cancer Stem Cells

Companies expect to commence first-in-human studies of Trx-1 in ovarian cancer in 1H15

Children's Oncology Drug Alliance (CODA) Formed To Facilitate Development Of Treatments For Childhood Cancers

Children's Oncology Drug Alliance (CODA) Formed To Facilitate Development Of Treatments For Childhood Cancers

Alliance of Australian and U.S. researchers and children's cancer advocates focused on developing drugs as potential treatments for neuroblastoma, the most common solid form of childhood cancer